Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...
February 15, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
February 10, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
January 19, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes...
December 30, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s Management Team On January 6, 2022

VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
September 17, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"

Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
September 13, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed...
April 27, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based...
March 03, 2021 18:00 ET | Source: InMed Pharmaceuticals Inc.

InMed to Present at Virtual Conferences in March 2021

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...
January 19, 2021 22:05 ET | Source: PMI

Global Bed Head Panel Market – Analysis and Demand with Forecast Overview to 2029 - by PMI

Covina CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The global bed head panel market for US$ 2.0 billion in 2019 is anticipated to register a CAGR of 5.5%. The report " Global Bed Head Panel Market, By...